| Autor: |
Usama E. Abuelhassan, Abdelrahman M. Abdalla, Abdulaziz Alfaifi, Sultan K. Kadasah, Mohammed A. Alshehri, Haneen A. Alasiri, Salihah Y. Al-Mani, Ali S. Kadasah, Abdullah Musleh, Fawwaz A. Alshafa, Muhammad S. S. Qureshi, Abdulmohsen Y. Assiri, Abdulrahman I. Falqi, Bader I. Asiri, Haider M. O. Ahmed, Saleem Alshehri, Fasih U. Rahman, Muhammad A. Qureshi, Omar Abdelwahab, Sherif Mohamed, Ahmed R. I. Ali, Saad M. A. Alqahtani, Medhat Elnamaky |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
The Egyptian Journal of Bronchology, Vol 18, Iss 1, Pp 1-9 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2314-8551 |
| DOI: |
10.1186/s43168-024-00341-7 |
| Popis: |
Abstract Background We aimed to study the impact of biological therapies in Saudi Arabia on patients with severe asthma (SA) combined with chronic rhinosinusitis (CRS) in terms of clinical outcomes. Methods This is a retrospective observational cohort research that was undertaken at the severe asthma clinics of the Armed Forces Hospital of the Southern Region (AFHSR) and King Khalid University Hospital, Abha, from March to September 2022 to delineate the effects of 3 biological therapies (dupilumab, benralizumab, and omalizumab) in adults with SA and concomitant CRS. Clinical outcomes assessed included asthma exacerbation frequency, hospitalization rates, use of oral corticosteroids (OCs), and the asthma control test (ACT) scores before and 1 year after biological therapies. Results Eighty patients were enrolled, with a mean age of 46.68. There were 45 (56%) females and 35 (44%) males. There was a notifiable decrease in the frequency of exacerbations and hospitalization and in the number of patients who received OCs after 6 and 12 months of biological therapies compared to pre-biological therapies, respectively (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
